Early access to investigational lung cancer drug for eligible patients
NCT ID NCT04830202
First seen Sep 30, 2025 · Last updated May 24, 2026 · Updated 29 times
Summary
This program provides early access to telisotuzumab vedotin, an investigational drug, for people with non-small cell lung cancer who have no other suitable treatment options and cannot join ongoing clinical trials. A doctor must decide if the potential benefits outweigh the risks for each patient. Availability depends on location.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.